Robert Torray’s BioMarin Pharmaceuticals BMRN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $4.45M | Sell |
77,705
-465
| -0.6% | -$25.5K | 0.6% | 41 |
|
|
2026
Q1 | $4.42M | Buy |
+78,170
| New | +$4.56M | 0.65% | 40 |
|
|
2024
Q3 | – | Sell |
-16,855
| Closed | -$1.39M | – | 103 |
|
|
2024
Q2 | $1.39M | Buy |
16,855
+2,019
| +14% | +$168K | 0.21% | 83 |
|
|
2024
Q1 | $1.3M | Buy |
14,836
+168
| +1% | +$15K | 0.19% | 83 |
|
|
2023
Q4 | $1.41M | Buy |
14,668
+446
| +3% | +$39.5K | 0.23% | 79 |
|
|
2023
Q3 | $1.26M | Buy |
14,222
+3,241
| +30% | +$288K | 0.22% | 78 |
|
|
2023
Q2 | $952K | Buy |
10,981
+104
| +1% | +$9.79K | 0.16% | 86 |
|
|
2023
Q1 | $1.06M | Buy |
10,877
+43
| +0.4% | +$4.46K | 0.19% | 87 |
|
|
2022
Q4 | $1.12M | Sell |
10,834
-466
| -4% | -$43.7K | 0.2% | 86 |
|
|
2022
Q3 | $958K | Sell |
11,300
-269
| -2% | -$24K | 0.19% | 87 |
|
|
2022
Q2 | $959K | Sell |
11,569
-18
| -0.2% | -$1.43K | 0.18% | 90 |
|
|
2022
Q1 | $893K | Sell |
11,587
-650
| -5% | -$54.4K | 0.14% | 93 |
|
|
2021
Q4 | $1.08M | Sell |
12,237
-4,166
| -25% | -$344K | 0.16% | 92 |
|
|
2021
Q3 | $1.27M | Buy |
16,403
+204
| +1% | +$16.1K | 0.19% | 91 |
|
|
2021
Q2 | $1.35M | Buy |
16,199
+142
| +0.9% | +$11.3K | 0.2% | 92 |
|
|
2021
Q1 | $1.21M | Sell |
16,057
-50,070
| -76% | -$4.09M | 0.19% | 94 |
|
|
2020
Q4 | $5.8M | Sell |
66,127
-2,263
| -3% | -$179K | 0.96% | 40 |
|
|
2020
Q3 | $5.2M | Buy |
68,390
+14,320
| +26% | +$1.45M | 0.96% | 42 |
|
|
2020
Q2 | $6.67M | Sell |
54,070
-6,472
| -11% | -$643K | 1.26% | 32 |
|
|
2020
Q1 | $5.12M | Buy |
60,542
+4,037
| +7% | +$348K | 1.13% | 35 |
|
|
2019
Q4 | $4.78M | Sell |
56,505
-145,450
| -72% | -$11M | 0.82% | 40 |
|
|
2019
Q3 | $13.6M | Buy |
201,955
+954
| +0.5% | +$73.5K | 1.48% | 38 |
|
|
2019
Q2 | $17.2M | Sell |
201,001
-19,086
| -9% | -$1.63M | 1.79% | 20 |
|
|
2019
Q1 | $19.6M | Sell |
220,087
-4,552
| -2% | -$422K | 2.06% | 16 |
|
|
2018
Q4 | $19.1M | Sell |
224,639
-12,632
| -5% | -$1.2M | 2.27% | 12 |
|
|
2018
Q3 | $23M | Sell |
237,271
-4,424
| -2% | -$442K | 2.3% | 10 |
|
|
2018
Q2 | $22.8M | Sell |
241,695
-8,301
| -3% | -$727K | 2.38% | 4 |
|
|
2018
Q1 | $20.3M | Buy |
249,996
+2,197
| +0.9% | +$189K | 2.1% | 13 |
|
|
2017
Q4 | $22.1M | Buy |
247,799
+19,003
| +8% | +$1.65M | 2.18% | 9 |
|
|
2017
Q3 | $21.3M | Buy |
228,796
+1,436
| +0.6% | +$127K | 2.11% | 10 |
|
|
2017
Q2 | $20.6M | Sell |
227,360
-19,125
| -8% | -$1.74M | 2.17% | 10 |
|
|
2017
Q1 | $21.6M | Sell |
246,485
-3,953
| -2% | -$352K | 2.27% | 11 |
|
|
2016
Q4 | $20.7M | Buy |
250,438
+55,546
| +29% | +$4.78M | 2.21% | 8 |
|
|
2016
Q3 | $18M | Sell |
194,892
-169,288
| -46% | -$15.9M | 1.98% | 18 |
|
|
2016
Q2 | $28.3M | Sell |
364,180
-83,820
| -19% | -$7.13M | 2.15% | 18 |
|
|
2016
Q1 | $37M | Buy |
448,000
+218,035
| +95% | +$17.7M | 1.93% | 27 |
|
|
2015
Q4 | $24.1M | Buy |
229,965
+2,120
| +0.9% | +$221K | 1.79% | 26 |
|
|
2015
Q3 | $24M | Sell |
227,845
-2,350
| -1% | -$314K | 1.76% | 28 |
|
|
2015
Q2 | $31.5M | Sell |
230,195
-26,260
| -10% | -$3.25M | 2.05% | 27 |
|
|
2015
Q1 | $32M | Sell |
256,455
-48,105
| -16% | -$5.1M | 3.74% | 10 |
|
|
2014
Q4 | $27.5M | Sell |
304,560
-46,335
| -13% | -$3.85M | 2.31% | 14 |
|
|
2014
Q3 | $25.3M | Buy |
350,895
+75,710
| +28% | +$4.98M | 2.3% | 18 |
|
|
2014
Q2 | $17.1M | Buy |
275,185
+210,380
| +325% | +$12.7M | 1.73% | 24 |
|
|
2014
Q1 | $4.42M | Buy |
+64,805
| New | +$4.78M | 0.75% | 57 |
|
Other funds holding BMRN
VPC
Robert Torray's BMRN Position: Q2 2026 in Review
Robert Torray reduced its BioMarin Pharmaceuticals (BMRN) stake by 0.59% in Q2 2026, selling an estimated $25.5K and leaving 77,705 shares worth $4.45M. The position accounts for 0.6% of the portfolio, ranked #41.
Robert Torray first reported a position in BMRN in Q1 2014 and has held it in 44 quarters since. The position peaked at $37M in Q1 2016. 561 funds tracked by Wall St. Rank hold BMRN as of Q2 2026.
- Robert Torray held 77,705 shares of BioMarin Pharmaceuticals worth $4.45M as of Q2 2026.
- Robert Torray sold 465 BioMarin Pharmaceuticals shares in Q2 2026, an estimated $25.5K.
- BioMarin Pharmaceuticals made up 0.6% of Robert Torray's portfolio in Q2 2026, its #41 holding.
- Robert Torray first reported a position in BioMarin Pharmaceuticals in Q1 2014 and has held it in 44 quarters since.
- Robert Torray's BioMarin Pharmaceuticals position peaked at $37M in Q1 2016.
- 561 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2026.
Based on Torray Investment Partners's 13F filing for Q2 2026, filed 30 Jul 2026.